Insulin pump therapy with and without continuous glucose monitoring in pregnant women with type 1 diabetes: a prospective observational Orchestra Foundation study in Poland

被引:4
|
作者
Cypryk, Katarzyna [1 ]
Wender-Ozegowska, Ewa [2 ]
Cyganek, Katarzyna [3 ,4 ]
Sieradzki, Jacek [4 ]
Skoczylas, Kinga [5 ]
Chen, Xiaoxiao [6 ]
Cordero, Toni L. L. [6 ]
Shin, John [6 ]
Cohen, Ohad [7 ]
机构
[1] Med Univ Lodz, Dept Internal Dis & Diabetol, Pomorska Str 251, PL-92213 Lodz, Poland
[2] Poznan Univ Med Sci, Dept Reprod, Poznan, Poland
[3] Univ Hosp Krakow, Dept Metab Dis, Krakow, Poland
[4] Jagiellonian Univ Krakow, Coll Med, Krakow, Poland
[5] Medtronic, Warsaw, Poland
[6] Medtronic, Northridge, CA USA
[7] Medtronic, Tolochenaz, Switzerland
关键词
Type 1 diabetes-complicated pregnancy; HbA1c; Continuous subcutaneous insulin infusion (CSII); Continuous glucose monitoring (CGM); Large for gestational age (LGA); Neonatal outcomes; GLYCEMIC CONTROL; SEVERE HYPOGLYCEMIA; OUTCOMES; INFUSION; RISK; MELLITUS; IMPLEMENTATION; KETOACIDOSIS; PREECLAMPSIA; ASSOCIATION;
D O I
10.1007/s00592-022-02020-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsThe effects of continuous subcutaneous insulin infusion (CSII) therapy with or without continuous glucose monitoring (CGM) on neonatal outcomes and glycemic outcomes of pregnant women with type 1 diabetes (T1D), living in Poland, were assessed.MethodsThis prospective observational study enrolled women with T1D (N = 481, aged 18-45 years) who were pregnant or planned pregnancy. All used CSII therapy and a subset used CGM with CSII (CSII + CGM). Neonatal outcomes (e.g., rate of large for gestational age [LGA] delivery [birth weight > 90th percentile]) and maternal glycemia (e.g., HbA1c and percentage of time at sensor glucose ranges) were evaluated.ResultsOverall HbA1c at trimesters 1, 2, and 3 was 6.8 +/- 1.1% (50.9 +/- 12.3 mmol/mol, N = 354), 5.8 +/- 0.7% (40.1 +/- 8.0 mmol/mol, N = 318), and 5.9 +/- 0.7% (41.4 +/- 8.0 mmol/mol, N = 255), respectively. A HbA1c target of < 6.0% (42 mmol/mol) at each trimester was achieved by 20.9% (74/354), 65.1% (207/318), and 58.0% (148/255), respectively. For women using CSII + CGM versus CSII only, HbA1c levels at trimesters 1, 2, and 3 were 6.5 +/- 0.9% versus 7.1 +/- 1.3% (47.8 +/- 9.7 mmol/mol versus 54.3 +/- 14.0 mmol/mol, p < 0.0001), 5.7 +/- 0.6% versus 6.0 +/- 0.9% (38.9 +/- 6.5 mmol/mol versus 41.6 +/- 9.3 mmol/mol, p = 0.0122), and 5.8 +/- 0.6% versus 6.1 +/- 0.8% (40.3 +/- 6.9 mmol/mol versus 42.9 +/- 9.1 mmol/mol, p = 0.0117), respectively. For the overall, CSII only, and CSII + CGM groups, rates of LGA delivery were 22.7% (74/326), 24.6% (34/138), and 21.3% (40/188), respectively.ConclusionsObservational assessment of women with T1D using CSII therapy demonstrated low HbA1c throughout pregnancy and low rates of LGA. The addition of CGM to CSII therapy compared to CSII therapy alone was associated with some improved maternal glycemic and neonatal outcomes.Clinicaltrials.gov identifierNCT01779141 (January 2013).
引用
收藏
页码:553 / 561
页数:9
相关论文
共 50 条
  • [41] Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes
    McQueen R.B.
    Ellis S.L.
    Campbell J.D.
    Nair K.V.
    Sullivan P.W.
    Cost Effectiveness and Resource Allocation, 9 (1)
  • [42] Continuous glucose monitoring in pregnant women with pregestational type 2 diabetes: a narrative review
    Ye, Sylvia
    Shahid, Ibrahim
    Yates, Christopher J.
    Kevat, Dev
    Lee, I-Lynn
    OBSTETRIC MEDICINE, 2024, 17 (04) : 194 - 200
  • [43] Satisfaction with Continuous Glucose Monitoring in Pregnant Patients with Type 1 and Type 2 Diabetes
    Shrestha, Kevin S.
    Battarbee, Ashley N.
    AMERICAN JOURNAL OF PERINATOLOGY, 2024,
  • [44] Satisfaction with continuous glucose monitoring in pregnant patients with type 1 and type 2 diabetes
    Shrestha, Kevin S.
    Battarbee, Ashley N.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 230 (01) : S183 - S184
  • [45] CONTINUOUS GLUCOSE MONITORING METRICS AND NEONATAL OUTCOMES IN PREGNANT WOMEN WITH INSULIN-TREATED DIABETES
    Citro, F.
    Nicoli, F.
    Bianchi, C.
    Aragona, M.
    Battini, L.
    Del Prato, S.
    Bertolotto, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A58 - A58
  • [46] Technological Developments and Quality of Life in Type 1 Diabetes Mellitus Patients: A Review of the Modern Insulin Analogues, Continuous Glucose Monitoring and Insulin Pump Therapy
    Benioudakis, Emmanouil
    Karlafti, Eleni
    Kalaitzaki, Argyroula
    Kaiafa, Georgia
    Savopoulos, Christos
    Didangelos, Triantafyllos
    CURRENT DIABETES REVIEWS, 2022, 18 (07)
  • [47] THE DAILY REQUIREMENT OF BASAL INSULIN IN PREGNANT WOMEN WITH TYPE 1 DIABETES RECEIVING INSULIN BY THE PUMP
    Valeeva, F.
    Sharipova, Y. U.
    Alimetova, Z. R.
    Gaysina, L. R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A68 - A69
  • [48] A review of CONCEPTT study findings including subanalyses in pregnant women using continuous glucose monitoring with type 1 diabetes and their offspring
    Pham, David Q.
    Thorsell, Ashley
    Castorino, Kristin
    Cobb, Brandon
    ENDOCRINE CONNECTIONS, 2024, 13 (02)
  • [49] Continuous Glucose Monitor Use With Remote Monitoring Reduces Fear of Hypoglycemia in Pregnant Women With Type 1 Diabetes: A Pilot Study
    Polsky, Sarit
    Garcetti, Rachel
    Pyle, Laura
    Joshee, Prakriti
    Demmitt, Jamie K.
    Snell-Bergeon, Janet K.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (01): : 191 - 192
  • [50] Glucose Variability: Insulin Pump vs. Multiple Daily Injection in Type 1 Diabetes Evaluated by Continuous Glucose Monitoring
    Proietti, Adrian E., Sr.
    Daghero, Andrea V., Sr.
    Scapuzzi, Maria Lujan
    Iglesias, Maria L., Sr.
    Nogueira, Juan Patricio, Sr.
    DIABETES, 2019, 68